10x Genomics, Inc. (LON:0A88)
London
· Delayed Price · Currency is GBP · Price in USD 11.14
-0.70 (-5.93%)
At close: Feb 21, 2025
10x Genomics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Revenue | 610.79 | 618.73 | 516.41 | 490.49 | 298.85 | Upgrade
|
| Revenue Growth (YoY) | -1.28% | 19.81% | 5.28% | 64.13% | 21.53% | Upgrade
|
| Cost of Revenue | 196 | 209.41 | 120.09 | 74.09 | 58.47 | Upgrade
|
| Gross Profit | 414.78 | 409.31 | 396.32 | 416.4 | 240.38 | Upgrade
|
| Selling, General & Admin | 343.24 | 343.33 | 295.8 | 257.56 | 202.33 | Upgrade
|
| Research & Development | 264 | 265.73 | 264.27 | 211.75 | 123.38 | Upgrade
|
| Operating Expenses | 607.24 | 609.06 | 560.07 | 469.31 | 325.7 | Upgrade
|
| Operating Income | -192.46 | -199.75 | -163.74 | -52.91 | -85.32 | Upgrade
|
| Interest Expense | -0 | -0.03 | -0.48 | -0.87 | -1.68 | Upgrade
|
| Interest & Investment Income | 18.45 | 16.91 | 6.65 | 0.21 | 1.53 | Upgrade
|
| Currency Exchange Gain (Loss) | -2.1 | 1.2 | 0.2 | -0.9 | 1.3 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.52 | 0.21 | -0.4 | 0.1 | 0.04 | Upgrade
|
| EBT Excluding Unusual Items | -175.6 | -181.47 | -157.77 | -54.38 | -84.14 | Upgrade
|
| Merger & Restructuring Charges | - | - | -4.2 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -0 | -1.72 | - | - | - | Upgrade
|
| Asset Writedown | -2.1 | -4.6 | - | - | - | Upgrade
|
| Legal Settlements | - | - | - | 0.66 | -1.27 | Upgrade
|
| Other Unusual Items | - | - | - | - | -1.52 | Upgrade
|
| Pretax Income | -177.7 | -248.76 | -161.97 | -53.72 | -534.48 | Upgrade
|
| Income Tax Expense | 4.93 | 6.34 | 4.03 | 4.51 | 8.26 | Upgrade
|
| Net Income | -182.63 | -255.1 | -166 | -58.22 | -542.73 | Upgrade
|
| Net Income to Common | -182.63 | -255.1 | -166 | -58.22 | -542.73 | Upgrade
|
| Shares Outstanding (Basic) | 120 | 117 | 114 | 110 | 101 | Upgrade
|
| Shares Outstanding (Diluted) | 120 | 117 | 114 | 110 | 101 | Upgrade
|
| Shares Change (YoY) | 2.81% | 2.90% | 3.18% | 9.09% | 158.76% | Upgrade
|
| EPS (Basic) | -1.52 | -2.18 | -1.46 | -0.53 | -5.37 | Upgrade
|
| EPS (Diluted) | -1.52 | -2.18 | -1.46 | -0.53 | -5.37 | Upgrade
|
| Free Cash Flow | -5.73 | -63.8 | -165.27 | -122.65 | -254.56 | Upgrade
|
| Free Cash Flow Per Share | -0.05 | -0.54 | -1.45 | -1.11 | -2.52 | Upgrade
|
| Gross Margin | 67.91% | 66.15% | 76.75% | 84.89% | 80.44% | Upgrade
|
| Operating Margin | -31.51% | -32.28% | -31.71% | -10.79% | -28.55% | Upgrade
|
| Profit Margin | -29.90% | -41.23% | -32.15% | -11.87% | -181.61% | Upgrade
|
| Free Cash Flow Margin | -0.94% | -10.31% | -32.00% | -25.01% | -85.18% | Upgrade
|
| EBITDA | -156.58 | -164.24 | -138.38 | -31.8 | -71.31 | Upgrade
|
| EBITDA Margin | -25.64% | -26.54% | -26.80% | -6.48% | -23.86% | Upgrade
|
| D&A For EBITDA | 35.88 | 35.51 | 25.37 | 21.12 | 14.01 | Upgrade
|
| EBIT | -192.46 | -199.75 | -163.74 | -52.91 | -85.32 | Upgrade
|
| EBIT Margin | -31.51% | -32.28% | -31.71% | -10.79% | -28.55% | Upgrade
|
| Advertising Expenses | 3.9 | 3.3 | 3.7 | 4.7 | 1.9 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.